Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

Overview

Información sobre este estudio

The purpose of this post-market surveillance study is to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Parent or LAR has signed information consent

- Subject weighs between 2.5-10 kg (or 5.5-22 lbs)

- Subject is receiving medical care in an intensive care unit

- Parental or LAR consent to receive full supportive care through aggressive management
utilizing all available therapies for a minimum of 96 hours

- Subject has a clinical diagnosis of acute kidney injury per Kidney Disease Improving
Global Outcomes (KDIGO) criteria or fluid overload requiring CRRT

Exclusion Criteria:

- Subject is not expected to survive 72 hours due to an irreversible medical condition,
in the opinion of the investigator

- Subject has irreversible brain damage, in the opinion of the investigator

- Subject is intolerant to anticoagulation, as documented in the medical record

- Subject has a Do Not Attempt Resuscitate (DNAR), Allow Natural Death (AND), withdrawal
of care or similar order, or anticipated change in status, in the opinion of the
investigator, within the next 7 days

- Subject has pre-existing end-stage renal disease or pre-existing, advanced chronic
kidney disease, defined as an estimated Glomerular Filtration Rate (eGRF) < 30
ml/min/1.73m2

- Subject is currently or has chronically been treated with a circulatory support device
(i.e., left ventricular assist device (LVAD)) other than ECMO

- Subject has had prior CRRT treatments using the Carpediem? system

- Subject is enrolled in clinical trials or being treated with other investigational
therapeutic devices or products for acute kidney injury or fluid overload

- Subject has any other medical condition that may confound the study objectives, in the
opinion of the investigator

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/22/2024. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Cheryl Tran, M.D.

Abierto para la inscripción

Contact information:

Justin Patri CCRP

(507) 293-3732

Patri.Justin@mayo.edu

More information

Publicaciones

Publications are currently not available
.
CLS-20530082

Mayo Clinic Footer